Polycystic Ovarian Syndrome Market Research Report – Forecast to 2030

Polycystic Ovarian Syndrome Market Research Report, By Diagnosis (Pelvic Examination, Ultrasound, Blood Tests), Treatment (Oral Contraceptives, Antiandrogens), End-User (Hospitals & Clinics, Ambulatory Surgical Centers) – Global Forecast Till 2030

ID: MRFR/Pharma/4834-HCR | | Region: Global | 100 Pages         

Polycystic Ovarian Syndrome Market Speak to Analyst Request a Free Sample

Polycystic Ovarian Syndrome Market Overview The Polycystic Ovarian Syndrome Market is anticipated to reach USD 3468.54 Million by 2030 at 4.80% CAGR during the forecast period 2022-2030. Polycystic Ovary Syndrome (PCOS) is a medical illness that causes hormonal imbalances in women of reproductive age. This is caused by a rise in male hormone levels in the body, resulting in an irregular menstrual cycle. Symptoms include an irregular menstrual cycle, increased facial hair growth, acne, thinning or hair loss on the scalp, weight gain, skin discoloration, and more. High levels of androgens, excess insulin, low-grade inflammation, ovarian cysts, and genetic abnormalities all contribute to Polycystic Ovary Syndrome (PCOS). PCOS is a hormonal endocrine condition that primarily affects women of reproductive age (15 to 49 years). PCOS is the most prevalent cause of female infertility, according to the Centers for Disease Control and Prevention (CDC). The rising prevalence of PCOS and the lack of tailored PCOS treatments on the market necessitate the development of new treatment options. Because of the increased prevalence of polycystic ovarian syndrome, the market for the polycystic ovarian syndrome is predicted to rise rapidly. Other significant reasons contributing to market expansion include rising obesity among women, rising diabetes prevalence, rising hormonal disorders in women, change in sedentary lifestyle, socioeconomic factors, rising consumption of poor diet, and others. Another condition that contributes to the development of polycystic ovarian syndrome is diabetes.

Segmentation


The polycystic ovarian syndrome market is segmented on the basis of diagnosis, treatment, and end-user. The polycystic ovarian syndrome market, by diagnosis, is categorized into the pelvic examination, transvaginal ultrasound, and blood tests. Blood tests are further sub-segmented into hormone levels, glucose tolerance and cholesterol and triglyceride levels. On the basis of treatment, the market is segmented into oral contraceptives, antiandrogens, insulin-sensitizing agents, antidepressant, anti-obesity, and surgery. The surgery category includes ovarian wedge resection and laparoscopic ovarian drilling. On the basis of end-user, the market is segmented into hospitals and clinics, ambulatory surgical centers, diagnostic centers, gynecology centers, feminist health centers, and others.  


On the basis of region, the polycystic ovarian syndrome market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas is sub-segmented into North America and South America. The North American region is further segmented into the US and Canada. The European region is divided into two, namely, Western Europe and Eastern Europe. Western Europe is further classified into Germany, Italy, France, the UK, Spain, and the rest of Western Europe. The Asia-Pacific region is sub-segmented into Japan, China, India, Australia, the Republic of Korea, and the rest of Asia-Pacific. The Middle Eastern and African region is sub-segmented into the United Arab Emirates, Saudi Arabia, Oman, Kuwait, Qatar, and the rest of the Middle East and Africa.


Key players


Some of the key players in the polycystic ovarian syndrome market are Bayer AG, AstraZeneca plc, Abbott, Biocinese, Catalysis, S.L., Crinetics Pharmaceuticals, Inc., Sanofi, Eugonia, EffRx, Inc., Ferring Pharmaceuticals, Inc., Merck KGaA, Bristol-Myer Squibb Company, Neurocrine Biosciences, Inc., Reliance Life Sciences Pvt. Ltd. Pfizer, Inc., Novartis AG, and Shire Plc.


Regional Market Summary


Polycystic Ovarian Syndrome Market Share (%), by Region, 2017


Polycystic Ovarian Syndrome Market Share


Sources: Center for Disease Control and Prevention, Office on Women's Health, Office of the Assistant Secretary for Health, US Department of Health and Human Services.


The polycystic ovarian syndrome market is dominated by North America owing to the rising obesity. According to the Institute for Health Metrics and Evaluation (IHME), 60% of women were obese or overweight in 2013. Other factors such as increasing healthcare expenditure, increasing technological advancements, and adoption of minimally invasive surgeries drive the market growth in this region.


It is estimated that Europe was the second largest in the polycystic ovarian syndrome market owing to the increasing prevalence of diabetes, obesity, and increasing research activities in the health industry in this region. According to the German Federal Ministry of Health in 2014 and 2015, 7.0% of women of age 18 and more suffered from diabetes in Germany. Thus, the increasing prevalence of diabetes in this region influences the growth of this market in this region.


Asia-Pacific was projected to be the fastest growing region for the polycystic ovarian syndrome market in 2017. The market is expected to witness growth owing to the rising prevalence of diabetes in women, changing lifestyle, and growing obesity within the female population. This provides favorable backgrounds for the market to grow.


The Middle East and Africa holds the least share in the polycystic ovarian syndrome market due to the presence of stringent government policies and poor economies. However, the market is expected to witness growth due to the rising healthcare expenditure, growing private sector in the healthcare domain, and insurance coverage in the Middle East.


Market Segmentation and Key Market Players


Polycystic Ovarian Syndrome Market, by Diagnosis



  • Pelvic examination

  • Transvaginal ultrasound

  • Blood tests


    • Hormone levels

    • Glucose tolerance

    • Cholesterol and triglyceride levels



Polycystic Ovarian Syndrome Market, by Treatment



  • Oral Contraceptives

  • Antiandrogens

  • Insulin Sensitizing Agent

  • Antidepressant

  • Anti-Obesity

  • Surgery


    • Ovarian Wedge Resection

    • Laparoscopic Ovarian Drilling



Polycystic Ovarian Syndrome Market, by End-User



  • Hospitals & Clinics

  • Ambulatory Surgical Centers

  • Diagnostic Centers

  • Gynecology Centers

  • Feminist Health Centers


Polycystic Ovarian Syndrome Market, by Region



  • Americas

  • Europe

  • Asia-Pacific

  • Middle East & Africa


Recent Development


In January 2020, Evotec SE and Bayer AG launched a new five-year, multi-target collaboration with Celmatix Inc. to develop numerous clinical candidates for the treatment of polycystic ovarian syndrome, which is projected to drive the market throughout the forecast period. Abbvie has an ongoing clinical trial using the chemical Elagolix in the pipeline in January 2020, which was being examined for its safety and efficacy in women with the polycystic ovarian syndrome. The business is now conducting a Phase 2 multicenter, double-blind, randomized, placebo-controlled research to evaluate Elagolix's safety and efficacy in women with the polycystic ovarian syndrome (PCOS).

Intended Audience



  • Pharmaceutical companies

  • Biotechnological institutes

  • Government and private laboratories

  • Research and Development (R&D) companies

  • Medical research laboratories

  • Market research and consulting service providers



Report Scope:

Report Attribute/Metric Details
  Market Size   USD 3468.54 Million
  CAGR   4.80%
  Base Year   2021
  Forecast Period   2022-2030
  Historical Data   2020
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   By Diagnosis, Treatment, End-User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Bayer AG, AstraZeneca plc, Abbott, Biocinese, Catalysis, S.L., Crinetics Pharmaceuticals, Inc., Sanofi, Eugonia, EffRx, Inc., Ferring Pharmaceuticals, Inc., Merck KGaA, Bristol-Myer Squibb Company, Neurocrine Biosciences, Inc., Reliance Life Sciences Pvt. Ltd. Pfizer, Inc., Novartis AG, and Shire Plc
  Key Market Opportunities

  • Increasing healthcare expenditure
  • Increasing technological advancements
  •   Key Market Drivers

  • Increasing hormonal disorders in women
  • Adoption of minimally invasive surgeries
  • Rising prevalence of diabetes


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    North America is expected to lead the Polycystic Ovarian Syndrome Market.

    Increasing prevalence of diabetes and rising hormonal disorders among women is adding market growth.

    Different end use industries of Polycystic Ovarian Syndrome Market include feminist health centers, gynecology centers, hospitals and clinics, and others.

    Different strategies used by industry players to create a dominance in the Polycystic Ovarian Syndrome Market include mergers, collaborations, strategic alliances, and product launches.